Alpha-Adrenergic Agonists Stimulate Fluid Secretion in Lacrimal Gland Ducts. 2020

Dóra Szarka, and Gréta Elekes, and Orsolya Berczeli, and Eszter Vizvári, and László Szalay, and Chuanqing Ding, and László Tálosi, and Edit Tóth-Molnár
Department of Ophthalmology, University of Szeged, Szeged, Hungary.

The role of adrenergic innervation in the regulation of lacrimal gland (LG) ductal fluid secretion is unknown. The Aim of the present study was to investigate the effect of adrenergic stimulation on fluid secretion in isolated LG duct segments and to study the underlying intracellular mechanisms. Fluid secretion of isolated mouse LG ducts was measured using video-microscopy. Effect of various adrenergic agonists (norepinephrine, phenylephrine, and isoproterenol) on fluid secretion as well as inhibitory effects of specific antagonists on adrenergic agonist-stimulated secretory response were analyzed. Changes in intracellular Ca2+ level [Ca2+i] were investigated with microfluorometry. Both norepinephrine and phenylephrine initiated a rapid and robust fluid secretory response, whereas isoproterenol did not cause any secretion. Phenylephrine-induced secretion was completely blocked by α1D-adrenergic receptor blocker BMY-7378. The endothelial nitric oxide synthase (eNOS) inhibitor L-NAME or guanylyl cyclase inhibitor ODQ reduced but not completely abolished the phenylephrine-induced fluid secretion, whereas co-administration of Ca2+-chelator BAPTA-AM resulted in a complete blockade. Phenylephrine stimulation induced a small, but statistically significant elevation in [\(Ca_i^{2 + }\)]. Our results prove the direct role of α1-adrenergic stimulation on LG ductal fluid secretion. Lack of isoproterenol-induced fluid secretory response suggests the absence of β-receptor mediated pathway in mouse LG ducts. Complete blockade of phenylephrine-induced fluid secretion by BMY-7378 and predominant inhibition of the secretory response either by L-NAME or ODQ suggest that α-adrenergic agonists use the NO/cGMP pathway through α1D receptor. Ca2+ signaling independent from NO/cGMP pathway may also play an at least partial role in α-adrenergic induced ductal fluid secretion.

UI MeSH Term Description Entries
D007765 Lacrimal Apparatus The tear-forming and tear-conducting system which includes the lacrimal glands, eyelid margins, conjunctival sac, and the tear drainage system. Lacrimal Gland,Nasolacrimal Apparatus,Conjunctival Sacs,Lacrimal Ducts,Lacrimal Punctum,Lateral Canthus,Medial Canthus,Apparatus, Lacrimal,Apparatus, Nasolacrimal,Canthus, Lateral,Canthus, Medial,Conjunctival Sac,Duct, Lacrimal,Gland, Lacrimal,Lacrimal Duct,Lacrimal Glands,Lacrimal Punctums,Punctum, Lacrimal,Sac, Conjunctival
D009301 Nasolacrimal Duct A tubular duct that conveys TEARS from the LACRIMAL GLAND to the nose. Lacrimal Sac,Tear Duct,Duct, Nasolacrimal,Duct, Tear,Ducts, Nasolacrimal,Ducts, Tear,Lacrimal Sacs,Nasolacrimal Ducts,Sac, Lacrimal,Sacs, Lacrimal,Tear Ducts
D009638 Norepinephrine Precursor of epinephrine that is secreted by the ADRENAL MEDULLA and is a widespread central and autonomic neurotransmitter. Norepinephrine is the principal transmitter of most postganglionic sympathetic fibers, and of the diffuse projection system in the brain that arises from the LOCUS CERULEUS. It is also found in plants and is used pharmacologically as a sympathomimetic. Levarterenol,Levonorepinephrine,Noradrenaline,Arterenol,Levonor,Levophed,Levophed Bitartrate,Noradrenaline Bitartrate,Noradrénaline tartrate renaudin,Norepinephrin d-Tartrate (1:1),Norepinephrine Bitartrate,Norepinephrine Hydrochloride,Norepinephrine Hydrochloride, (+)-Isomer,Norepinephrine Hydrochloride, (+,-)-Isomer,Norepinephrine d-Tartrate (1:1),Norepinephrine l-Tartrate (1:1),Norepinephrine l-Tartrate (1:1), (+,-)-Isomer,Norepinephrine l-Tartrate (1:1), Monohydrate,Norepinephrine l-Tartrate (1:1), Monohydrate, (+)-Isomer,Norepinephrine l-Tartrate (1:2),Norepinephrine l-Tartrate, (+)-Isomer,Norepinephrine, (+)-Isomer,Norepinephrine, (+,-)-Isomer
D010656 Phenylephrine An alpha-1 adrenergic agonist used as a mydriatic, nasal decongestant, and cardiotonic agent. (R)-3-Hydroxy-alpha-((methylamino)methyl)benzenemethanol,Metaoxedrin,Metasympatol,Mezaton,Neo-Synephrine,Neosynephrine,Phenylephrine Hydrochloride,Phenylephrine Tannate,Neo Synephrine,Tannate, Phenylephrine
D010879 Piperazines Compounds that are derived from PIPERAZINE.
D002118 Calcium A basic element found in nearly all tissues. It is a member of the alkaline earth family of metals with the atomic symbol Ca, atomic number 20, and atomic weight 40. Calcium is the most abundant mineral in the body and combines with phosphorus to form calcium phosphate in the bones and teeth. It is essential for the normal functioning of nerves and muscles and plays a role in blood coagulation (as factor IV) and in many enzymatic processes. Coagulation Factor IV,Factor IV,Blood Coagulation Factor IV,Calcium-40,Calcium 40,Factor IV, Coagulation
D003592 Cytophotometry A method for the study of certain organic compounds within cells, in situ, by measuring the light intensities of the selectively stained areas of cytoplasm. The compounds studied and their locations in the cells are made to fluoresce and are observed under a microscope. Microfluorometry,Cytophotometries,Microfluorometries
D004533 Egtazic Acid A chelating agent relatively more specific for calcium and less toxic than EDETIC ACID. EGTA,Ethylene Glycol Tetraacetic Acid,EGATA,Egtazic Acid Disodium Salt,Egtazic Acid Potassium Salt,Egtazic Acid Sodium Salt,Ethylene Glycol Bis(2-aminoethyl ether)tetraacetic Acid,Ethylenebis(oxyethylenenitrile)tetraacetic Acid,GEDTA,Glycoletherdiamine-N,N,N',N'-tetraacetic Acid,Magnesium-EGTA,Tetrasodium EGTA,Acid, Egtazic,EGTA, Tetrasodium,Magnesium EGTA
D000316 Adrenergic alpha-Agonists Drugs that selectively bind to and activate alpha adrenergic receptors. Adrenergic alpha-Receptor Agonists,alpha-Adrenergic Receptor Agonists,Adrenergic alpha-Agonist,Adrenergic alpha-Receptor Agonist,Receptor Agonists, Adrenergic alpha,Receptor Agonists, alpha-Adrenergic,alpha-Adrenergic Agonist,alpha-Adrenergic Agonists,alpha-Adrenergic Receptor Agonist,Adrenergic alpha Agonist,Adrenergic alpha Agonists,Adrenergic alpha Receptor Agonist,Adrenergic alpha Receptor Agonists,Agonist, Adrenergic alpha-Receptor,Agonist, alpha-Adrenergic,Agonist, alpha-Adrenergic Receptor,Agonists, Adrenergic alpha-Receptor,Agonists, alpha-Adrenergic,Agonists, alpha-Adrenergic Receptor,Receptor Agonist, alpha-Adrenergic,Receptor Agonists, alpha Adrenergic,alpha Adrenergic Agonist,alpha Adrenergic Agonists,alpha Adrenergic Receptor Agonist,alpha Adrenergic Receptor Agonists,alpha-Agonist, Adrenergic,alpha-Agonists, Adrenergic,alpha-Receptor Agonist, Adrenergic,alpha-Receptor Agonists, Adrenergic
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

Dóra Szarka, and Gréta Elekes, and Orsolya Berczeli, and Eszter Vizvári, and László Szalay, and Chuanqing Ding, and László Tálosi, and Edit Tóth-Molnár
May 1986, The American journal of physiology,
Dóra Szarka, and Gréta Elekes, and Orsolya Berczeli, and Eszter Vizvári, and László Szalay, and Chuanqing Ding, and László Tálosi, and Edit Tóth-Molnár
January 2003, American journal of physiology. Cell physiology,
Dóra Szarka, and Gréta Elekes, and Orsolya Berczeli, and Eszter Vizvári, and László Szalay, and Chuanqing Ding, and László Tálosi, and Edit Tóth-Molnár
May 2011, Investigative ophthalmology & visual science,
Dóra Szarka, and Gréta Elekes, and Orsolya Berczeli, and Eszter Vizvári, and László Szalay, and Chuanqing Ding, and László Tálosi, and Edit Tóth-Molnár
August 1987, Pflugers Archiv : European journal of physiology,
Dóra Szarka, and Gréta Elekes, and Orsolya Berczeli, and Eszter Vizvári, and László Szalay, and Chuanqing Ding, and László Tálosi, and Edit Tóth-Molnár
June 1992, The American journal of physiology,
Dóra Szarka, and Gréta Elekes, and Orsolya Berczeli, and Eszter Vizvári, and László Szalay, and Chuanqing Ding, and László Tálosi, and Edit Tóth-Molnár
April 1994, Experimental eye research,
Dóra Szarka, and Gréta Elekes, and Orsolya Berczeli, and Eszter Vizvári, and László Szalay, and Chuanqing Ding, and László Tálosi, and Edit Tóth-Molnár
January 1998, Advances in experimental medicine and biology,
Dóra Szarka, and Gréta Elekes, and Orsolya Berczeli, and Eszter Vizvári, and László Szalay, and Chuanqing Ding, and László Tálosi, and Edit Tóth-Molnár
September 1988, Metabolism: clinical and experimental,
Dóra Szarka, and Gréta Elekes, and Orsolya Berczeli, and Eszter Vizvári, and László Szalay, and Chuanqing Ding, and László Tálosi, and Edit Tóth-Molnár
March 2022, Investigative ophthalmology & visual science,
Dóra Szarka, and Gréta Elekes, and Orsolya Berczeli, and Eszter Vizvári, and László Szalay, and Chuanqing Ding, and László Tálosi, and Edit Tóth-Molnár
June 1981, Biochimica et biophysica acta,
Copied contents to your clipboard!